SCHEMBL4745567

SCHEMBL4745567

COC1(C)CCC2(CC1)OCCO2

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.31
AVPR1A P37288 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2620631 0.78
Water SCHEMBL25401298 0.74
SCHEMBL1809810 0.74 L3MBTL1 (0.32) POLB
SCHEMBL2236435 0.74
SCHEMBL12346153 0.73 KDM4E (0.31)
SCHEMBL19066501 0.72 KMT2A (0.33)
SCHEMBL1564365 0.70
SCHEMBL6135374 0.70
SCHEMBL1701639 0.70
SCHEMBL21257861 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 US disclosed
US-20240166646-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES NEWAVE PHARMACEUTICAL INC. 2024-05-23 US disclosed
US-20240083917-A1 Polycyclic Kinase Inhibitor Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2024-03-14 US disclosed
EP-4289853-A1 POLYCYCLIC KINASE INHIBITOR Shandong Xuanzhu Pharma Co., Ltd. (CN) 2023-12-13 EP disclosed
EP-4289853-A1 POLYCYCLIC KINASE INHIBITOR Shandong Xuanzhu Pharma Co., Ltd. (CN) 2023-12-13 EP disclosed
CN-116669741-A Polycyclic kinase inhibitors 山东轩竹医药科技有限公司 2023-08-29 CN disclosed
WO-2023122000-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. (US) 2023-06-29 WO disclosed
WO-2022148354-A1 POLYCYCLIC KINASE INHIBITOR 山东轩竹医药科技有限公司 2022-07-14 WO disclosed
WO-2022148354-A1 POLYCYCLIC KINASE INHIBITOR 山东轩竹医药科技有限公司 2022-07-14 WO disclosed
WO-2022140224-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES NEWAVE PHARMACEUTICAL INC. (US) 2022-06-30 WO disclosed
EP-2373619-B1 GEMINAL ALKOXY/ALKYLSPIROCYCLIC SUBSTITUTED TETRAMIC ACID DERIVATES BAYER CROPSCIENCE AG (DE) 2014-09-10 EP disclosed
US-20140213795-A1 GERMINAL ALKOXY/ALKYLSPIROCYCLIC SUBSTITUTED TETRAMATE DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-07-31 US disclosed
US-20140213795-A1 GERMINAL ALKOXY/ALKYLSPIROCYCLIC SUBSTITUTED TETRAMATE DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-07-31 US disclosed
WO-2014053666-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2014-04-10 WO disclosed
US-8389443-B2 Geminal alkoxy/alkylspirocyclic substituted tetramate derivatives BAYER CROPSCIENCE AG (DE) 2013-03-05 US disclosed
US-8389443-B2 Geminal alkoxy/alkylspirocyclic substituted tetramate derivatives BAYER CROPSCIENCE AG (DE) 2013-03-05 US disclosed
US-20100261608-A1 Geminal alkoxy/alkylspirocyclic substituted tetramate derivatives BAYER CROPSCIENCE AG (DE) 2010-10-14 US disclosed
US-20100261608-A1 Geminal alkoxy/alkylspirocyclic substituted tetramate derivatives BAYER CROPSCIENCE AG (DE) 2010-10-14 US disclosed
WO-2008119716-A1 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed
WO-2008119716-A1 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166646-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES BCL2, BCL3, BCL2L1 POLB 740/4885AVPR1A 4557/4885
US-20250114374-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L10 POLB 2556/4885AVPR1A 4815/4885
US-20140213795-A1 GERMINAL ALKOXY/ALKYLSPIROCYCLIC SUBSTITUTED TETRAMATE DERIVATIVES AGXT, GMNN, GLRX3 POLB 1374/4885AVPR1A 3624/4885
US-20240083917-A1 Polycyclic Kinase Inhibitor PRKDC, DCK, DMPK POLB 286/4885AVPR1A 2930/4885
US-20100261608-A1 Geminal alkoxy/alkylspirocyclic substituted tetramate derivatives GMNN, AGXT, GEMIN5 POLB 1229/4885AVPR1A 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.